[1] |
NoHánělová K,Raudenská M,Masařík M,et al.Protein cargo in extracellular vesicles as the key mediator in the progression of cancer[J].Cell Commun Signal,2024,22(1): 25.DOI: 10.1186/s12964-023-01408-6.
|
[2] |
Kalluri R,LeBleu VS.The biology,function,and biomedical applications of exosomes[J].Science,2020,367(6478): eaau6977.DOI: 10.1126/science.aau6977.
|
[3] |
Miron RJ,Zhang Y.Understanding exosomes: part 1-characterization,quantification and isolation techniques[J].Periodontol 2000,2024,94(1): 231-256.DOI: 10.1111/prd.12520.
|
[4] |
de la Torre Gomez C,Goreham RV,Bech Serra JJ,et al.“Exosomics”-a review of biophysics,biology and biochemistry of exosomes with a focus on human breast milk[J].Front Genet,2018,9: 92.DOI:10.3389/fgene.2018.00092.
|
[5] |
Mathieu M,Martin-Jaular L,Lavieu G,et al.Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication[J].Nat Cell Biol,2019,21(1): 9-17.DOI:10.1038/s41556-018-0250-9.
|
[6] |
Zhou B,Xu K,Zheng X,et al.Application of exosomes as liquid biopsy in clinical diagnosis[J].Signal Transduct Target Ther,2020,5(1): 144.DOI: 10.1038/s41392-020-00258-9.
|
[7] |
Wang Y,Xiao T,Zhao C,et al.The regulation of exosome generation and function in physiological and pathological processes[J].Int J Mol Sci,2023,25(1): 255.DOI: 10.3390/ijms25010255.
|
[8] |
Mortezaee K,Majidpoor J.The impact of hypoxia on extracellular vesicle secretome profile of cancer[J].Med Oncol,2023,40(5): 128.DOI: 10.1007/s12032-023-01995-x.
|
[9] |
Liu Y,Shi K,Chen Y,et al.Exosomes and their role in cancer progression[J].Front Oncol,2021,11: 639159.DOI: 10.3389/fonc.2021.639159.
|
[10] |
Chu X,Yang Y,Tian X.Crosstalk between pancreatic cancer cells and cancer-associated fibroblasts in the tumor microenvironment mediated by exosomal microRNAs[J].Int J Mol Sci,2022,23(17):9512.Doi: 10.3390/ijms23179512.
|
[11] |
Han C,Zhang C,Wang H,et al.Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment[J].Oncoimmunology,2021,10(1):1887552.DOI: 10.1080/2162402X.2021.1887552.
|
[12] |
国家癌症中心,国家肿瘤质控中心前列腺癌质控专家委员会.中国前列腺癌规范诊疗质量控制指标(2022 版)[J].中华肿瘤杂志,2022,44(10): 1011-1016.DOI: 10.3760/cma.j.cn112152-20220803-00530.National Cancer Center,Prostate Cancer Expert Committee of National Cancer Quality Control Center.Quality control indicators of standardized diagnosis and treatment of prostate cancer in China(2022 edition)[J].Chin J Oncol,2022,44(10): 1011-1016.DOI:10.3760/cma.j.cn112152-20220803-00530.
|
[13] |
Wang G,Zhao D,Spring DJ,et al.Genetics and biology of prostate cancer[J].Genes Dev,2018,32(17-18): 1105-1140.DOI: 10.1101/gad.315739.118.
|
[14] |
Gong J,Chehrazi-Raffle A,Reddi S,et al.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy:a comprehensive review of registration trials and future considerations[J].J Immunother Cancer,2018,6(1): 8.DOI: 10.1186/s40425-018-0316-z.
|
[15] |
王超雄,郑培宣,赵允.病理激活的中性粒细胞上表达的CD300ld 参与肿瘤免疫抑制[J].中国细胞生物学学报,2023,45(11): 1593-1597.DOI: 10.11844/cjcb.2023.11.0001.Wang CX,Zheng PX,Zhao Y.The CD300ld receptor on pathologically activated neutrophils is required for tumor-driven immune suppression[J].Chin J Cell Biol,2023,45(11): 1593-1597.DOI: 10.11844/cjcb.2023.11.0001.
|
[16] |
Elia AR,Caputo S,Bellone M.Immune checkpoint-mediated interactions between cancer and immune cells in prostate adenocarcinoma and melanoma[J].Front Immunol,2018,9: 1786.DOI: 10.3389/fimmu.2018.01786.
|
[17] |
Silva JAF,Calmasini F,Siqueira-Berti A,et al.Prostate immunology:a challenging puzzle[J].J Reprod Immunol,2020,142: 103190.DOI:10.1016/j.jri.2020.103190.
|
[18] |
Qin S,Cao J,Ma X.Function and clinical application of exosomehow to improve tumor immunotherapy?[J].Front Cell Dev Biol,2023,11: 1228624.DOI: 10.3389/fcell.2023.1228624.
|
[19] |
Cui X,Fu Q,Wang X,et al.Molecular mechanisms and clinical applications of exosomes in prostate cancer[J].Biomark Res,2022,10(1):56.DOI: 10.1186/s40364-022-00398-w.
|
[20] |
Klibi J,Niki T,Riedel A,et al.Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells[J].Blood,2009,113(9): 1957-1966.DOI: 10.1182/blood-2008-02-142596.
|
[21] |
Paskeh MDA,Entezari M,Mirzaei S,et al.Emerging role of exosomes in cancer progression and tumor microenvironment remodeling[J].J Hematol Oncol,2022,15(1):83.DOI: 10.1186/s13045-022-01305-4.
|
[22] |
Lundholm M,Schröder M,Nagaeva O,et al.Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion[J].PLoS One,2014,9(9): e108925.DOI: 10.1371/journal.pone.0108925.
|
[23] |
Li N,Wang Y,Xu H,et al.Exosomes derived from RM-1 cells promote the recruitment of MDSCs into tumor microenvironment by upregulating CXCR4 via TLR2/NF-κ B pathway[J].J Oncol,2021,2021: 5584406.DOI: 10.1155/2021/5584406.
|
[24] |
Luo JQ,Yang TW,Wu J,et al.Exosomal PGAM1 promotes prostate cancer angiogenesis and metastasis by interacting with ACTG1[J].Cell Death Dis,2023,14(8): 502.DOI: 10.1038/s41419-023-06007-4.
|
[25] |
Xu F,Wang X,Huang Y,et al.Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell[J].Cell Rep,2023,42(11): 113424.DOI: 10.1016/j.celrep.2023.113424.
|
[26] |
Naito Y,Yoshioka Y,Yamamoto Y,et al.How cancer cells dictate their microenvironment: present roles of extracellular vesicles[J].Cell Mol Life Sci,2017,74(4): 697-713.DOI: 10.1007/s00018-016-2346-3.
|
[27] |
Webber J,Steadman R,Mason MD,et al.Cancer exosomes trigger fibroblast to myofibroblast differentiation[J].Cancer Res,2010,70(23): 9621-9630.DOI: 10.1158/0008-5472.CAN-10-1722.
|
[28] |
Sun C,Mezzadra R,Schumacher TN.Regulation and function of the PD-L1 checkpoint[J].Immunity,2018,48(3): 434-452.DOI:10.1016/j.immuni.2018.03.014.
|
[29] |
Guan H,Peng R,Fang F,et al.Tumor-associated macrophages promote prostate cancer progression via exosome-mediated miR-95 transfer[J].J Cell Physiol,2020,235(12): 9729-9742.DOI: 10.1002/jcp.29784.
|
[30] |
鲍子戌,周海胜.肿瘤细胞的EMT 与免疫逃逸的研究进展[J].生命的化学,2017,37(6): 980-985.DOI: 10.13488/j.smhx.20170617.Bao ZX,Zhou HS.The research progress of the EMT and immune escape of cancer cells[J].Chem Life,2017,37(6): 980-985.DOI:10.13488/j.smhx.20170617.
|
[31] |
Gaballa R,Ali HEA,Mahmoud MO,et al.Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchymal transition[J].Cancers,2020,12(8): 2300.DOI: 10.3390/cancers12082300.
|
[32] |
Lin CJ,Yun EJ,Lo UG,et al.The paracrine induction of prostate cancer progression by caveolin-1[J].Cell Death Dis,2019,10(11):834.DOI: 10.1038/s41419-019-2066-3.
|
[33] |
Pegtel DM,Gould SJ.Exosomes[J].Annu Rev Biochem,2019,88:487-514.DOI: 10.1146/annurev-biochem-013118-111902.
|
[34] |
Kim J,Morley S,Le M,et al.Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment[J].Cancer Biol Ther,2014,15(4): 409-418.DOI: 10.4161/cbt.27627.
|
[35] |
Li SL,An N,Liu B,et al.Exosomes from LNCaP cells promote osteoblast activity through miR-375 transfer[J].Oncol Lett,2019,17(5): 4463-4473.DOI: 10.3892/ol.2019.10110.
|
[36] |
Zhao H,Yang L,Baddour J,et al.Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism[J].eLife,2016,5: e10250.DOI: 10.7554/eLife.10250.
|
[37] |
Shao X,Hua S,Feng T,et al.Hypoxia-regulated tumor-derived exosomes and tumor progression: a focus on immune evasion[J].Int J Mol Sci,2022,23(19): 11789.DOI: 10.3390/ijms231911789.
|
[38] |
Josson S,Gururajan M,Sung SY,et al.Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis[J].Oncogene,2015,34(21): 2690-2699.DOI:10.1038/onc.2014.212.
|
[39] |
Zhang Y,Zhao J,Ding M,et al.Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis[J].J Exp Clin Cancer Res,2020,39(1): 282.DOI: 10.1186/s13046-020-01761-1.
|
[40] |
Vardaki I,Corn P,Gentile E,et al.Radium-223 treatment increases immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment[J].Clin Cancer Res,2021,27(11): 3253-3264.DOI: 10.1158/1078-0432.CCR-20-4790.
|
[41] |
Gururajan M,Josson S,Chu GC,et al.miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer[J].Clin Cancer Res,2014,20(24): 6559-6569.DOI: 10.1158/1078-0432.CCR-14-1784.
|
[42] |
Zhang G,Liu Y,Yang J,et al.Inhibition of circ_0081234 reduces prostate cancer tumor growth and metastasis via the miR-1/MAP 3 K1 axis[J].J Gene Med,2022,24(8): e3376.DOI: 10.1002/jgm.3376.
|
[43] |
Abd Elmageed ZY,Yang Y,Thomas R,et al.Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes[J].Stem Cells,2014,32(4): 983-997.DOI: 10.1002/stem.1619.
|
[44] |
Gong C,Zhang X,Shi M,et al.Tumor exosomes reprogrammed by low pH are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor[J].Adv Sci,2021,8(10): 2002787.DOI: 10.1002/advs.202002787.
|
[45] |
Yi M,Niu M,Xu L,et al.Regulation of PD-L1 expression in the tumor microenvironment[J].J Hematol Oncol,2021,14(1): 10.DOI:10.1186/s13045-020-01027-5.
|
[46] |
André F,Chaput N,Schartz NEC,et al.Exosomes as potent cellfree peptide-based vaccine.I.Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells[J].J Immunol,2004,172(4): 2126-2136.DOI: 10.4049/jimmunol.172.4.2126.
|
[47] |
Shi X,Sun J,Li H,et al.Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer[J].Prostate,2020,80(11): 811-823.DOI: 10.1002/pros.23996.
|
[48] |
Wang D,Wan Z,Yang Q,et al.Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes[J].Drug Deliv,2022,29(1): 702-713.DOI:10.1080/10717544.2022.2044937.
|
[49] |
Poggio M,Hu T,Pai CC,et al.Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory[J].Cell,2019,177(2): 414-427.e13.DOI: 10.1016/j.cell.2019.02.016.
|